Epstein-barr virus in oral shedding of children with multiple sclerosis

Neurology

Volumn 81, Issue 16, 2013, Pages 1392-1399

  Yea, Carmen ^a   Tellier, Raymond ^b,c   Chong, Patrick ^d   Westmacott, Garrett ^d   Marrie, Ruth Ann ^e   Bar Or, Amit ^f   Banwell, Brenda ^g  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c Alberta Provincial Public Health Laboratory   (Canada)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB;

ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DNA VIRUS; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; GENETIC VARIABILITY; HERPES SIMPLEX VIRUS 1; HERPES VIRUS INFECTION; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; MALE; MASS SPECTROMETRY; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; VIRUS SHEDDING;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; COMORBIDITY; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROSPECTIVE STUDIES; VIRAL MATRIX PROTEINS; VIRAL PROTEINS; VIRUS SHEDDING;

EID: 84888264120     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182a841e4     Document Type: Article

References (36)

1. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010;9:727-739.
2. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis: part I: The role of infection. Ann Neurol 2007;61:288-299.
3. Alotaibi S, Kennedy J, Tellier R, Stephens D, Banwell B. Epstein-Barr virus in pediatric multiple sclerosis. JAMA 2004;291:1875-1879.
4. Pohl D, Krone B, Rostasy K, et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 2006;67:2063-2065.
5. Banwell B, Krupp L, Kennedy J, et al. Clinical features and viral serologies in children with multiple sclerosis: A multinational observational study. Lancet Neurol 2007;6: 773-781.
6. Levin LI, Munger KL, Rubertone MV, et al. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005;293:2496-2500.
7. DeLorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH, Ascherio A. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 2006;63:839-844.
8. Knipe DM, Howley PM, Griffin DE, et al. Fields Virology, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007:2603-2654.
9. Hadinoto V, Shapiro M, Sun CC, Thorley-Lawson DA. The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog 2009;5:e1000496.
10. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000;343:481-492.
11. Jochum S, Moosmann A, Lang S, Hammerschmidt W, Zeidler R. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination. PLoS Pathog 2012;8:e1002704.
12. Yoon SI, Jones BC, Logsdon NJ, Harris BD, Kuruganti S, Walter MR. Epstein-Barr virus IL-10 engages IL-10R1 by a two-step mechanism leading to altered signaling properties. J Biol Chem 2012;287:26586-26595.
13. Graham JP, Arcipowski KM, Bishop GA. Differential B-lymphocyte regulation by CD40 and its viral mimic, latent membrane protein 1. Immunol Rev 2010;237:226-248.
14. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria." Ann Neurol 2005;58:840-846.
15. Johnson G, Nelson S, Petric M, Tellier R. Comprehensive PCR-based assay for detection and species identification of human herpesviruses. J Clin Microbiol 2000;38:3274- 3279.
16. Brooks JM, Croom-Carter DS, Leese AM, Tierney RJ, Habeshaw G, Rickinson AB. Cytotoxic T-lymphocyte responses to a polymorphic Epstein-Barr virus epitope identify healthy carriers with coresident viral strains. J Virol 2000;74:1801-1809.
17. Edwards RH, Seillier-Moiseiwitsch F, Raab-Traub N. Signature amino acid changes in latent membrane protein 1 distinguish Epstein-Barr virus strains. Virology 1999; 261:79-95.
18. Ayers M, Siu K, Roberts E, Garvin AM, Tellier R. Characterization of hepatitis C virus quasispecies by matrixassisted laser desorption ionization-time of flight (mass spectrometry) mutation detection. J Clin Microbiol 2002;40:3455-3462.
19. Thompson JD, Higgins DG, Gibson TJ. Clustal W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-4680.
20. Ward KN. The natural history and laboratory diagnosis of human herpesvirus-6 and -7 infections in the immunocompetent. J Clin Virol 2005;32:183-193.
21. Jilek S, Schluep M, Harari A, et al. HLA-B7-restricted EBV-specific CD81 T cells are dysregulated in multiple sclerosis. J Immunol 2012;188:4671-4680.
22. Ikuta K, Satoh Y, Hoshikawa Y, Sairenji T. Detection of Epstein-Barr virus in salivas and throat washings in healthy adults and children. Microbes Infect 2000;2:115-120.
23. Hug M, Dorner M, Fröhlich FZ, et al. Pediatric Epstein- Barr virus carriers with or without tonsillar enlargement may substantially contribute to spreading of the virus. J Infect Dis 2010;15:1192-1199.
24. Vogl BA, Fagin U, Nerbas L, Schlenke P, Lamprecht P, Jabs WJ. Longitudinal analysis of frequency and reactivity of Epstein-Barr virus-specific T lymphocytes and their association with intermittent viral reactivation. J Med Virol 2012; 84:119-131.
25. Santón A, Cristóbal E, Aparicio M, Royuela A, Villar LM, Alvarez-Cermeño JC. High frequency of co-infection by Epstein-Barr virus types 1 and 2 in patients with multiple sclerosis. Mult Scler 2011;17:1295-1300.
26. Brennan RM, Burrows JM, Bell MJ, et al. Strains of Epstein-Barr virus infecting multiple sclerosis patients. Mult Scler 2010;16:643-651.
27. Simon KC, Yang X, Munger KL, Ascherio A. EBNA1 and LMP1 variants in multiple sclerosis cases and controls. Acta Neurol Scand 2011;124:53-58.
28. Tzellos S, Farrell PJ. Epstein-Barr virus sequence variation: biology and disease. Pathogens 2012;1:156-174.
29. Salmaggi A, Dufour A, Eoli M, et al. Low serum interleukin- 10 levels in multiple sclerosis: further evidence for decreased systemic immunosuppression? J Neurol 1996;243:13-17.
30. Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 2010;67:452-461.
31. Whittington HA, Freeburn RW, Godinho SI, Egan J, Haider Y, Millar AB. Analysis of an IL-10 polymorphism in idiopathic pulmonary fibrosis. Genes Immun 2003;4: 258-264.
32. Kanai K, Satoh Y, Yamanaka H, et al. The vIL-10 gene of the Epstein-Barr virus (EBV) is conserved in a stable manner except for a few point mutations in various EBV isolates. Virus Genes 2007;35:563-569.
33. Mainou BA, Raab-Traub N. LMP1 strain variants: biological and molecular properties. J Virol 2006;80:6458-6468.
34. Ling PD, Lednicky JA, Keitel WA, et al. The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: A 14-month longitudinal study. J Infect Dis 2003;187:1571-1580.
35. Sitki-Green D, Covington M, Raab-Traub N. Compartmentalization and transmission of multiple Epstein-Barr virus strain in asymptomatic carriers. J Virol 2003;77: 1840-1847.
36. Huynh GT, Adler FR. Alternating host cell tropism shapes the persistence, evolution and coexistence of Epstein-Barr virus infections in human. Bull Math Biol 2011;73:1754-1773.